Delayed
Japan Exchange
10:30:00 2024-07-02 pm EDT
|
5-day change
|
1st Jan Change
|
3,570
JPY
|
+0.56%
|
|
+2.88%
|
+22.22%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
168,999
|
186,955
|
223,081
|
271,939
|
216,410
|
187,898
|
-
|
-
|
Enterprise Value (EV)
1 |
132,682
|
160,594
|
198,061
|
250,708
|
200,539
|
160,906
|
187,898
|
187,898
|
P/E ratio
|
15.1
x
|
50.1
x
|
31.3
x
|
50.3
x
|
-15.7
x
|
-24.5
x
|
9.25
x
|
15.1
x
|
Yield
|
1.11%
|
0.88%
|
0.49%
|
0.81%
|
1.02%
|
1.48%
|
1.41%
|
1.69%
|
Capitalization / Revenue
|
0.35
x
|
0.39
x
|
0.55
x
|
0.61
x
|
0.42
x
|
0.29
x
|
0.34
x
|
0.34
x
|
EV / Revenue
|
0.35
x
|
0.39
x
|
0.55
x
|
0.61
x
|
0.42
x
|
0.29
x
|
0.34
x
|
0.34
x
|
EV / EBITDA
|
5.23
x
|
6.11
x
|
9.24
x
|
10.1
x
|
6.59
x
|
4.84
x
|
5.45
x
|
5.61
x
|
EV / FCF
|
39.6
x
|
27.1
x
|
-670
x
|
-65.6
x
|
72.4
x
|
49.1
x
|
39
x
|
11.2
x
|
FCF Yield
|
2.52%
|
3.69%
|
-0.15%
|
-1.52%
|
1.38%
|
2.04%
|
2.56%
|
8.94%
|
Price to Book
|
1.86
x
|
2.14
x
|
2.17
x
|
2.43
x
|
2.25
x
|
1.83
x
|
1.76
x
|
1.65
x
|
Nbr of stocks (in thousands)
|
54,959
|
54,987
|
55,014
|
55,328
|
55,348
|
52,929
|
-
|
-
|
Reference price
2 |
3,075
|
3,400
|
4,055
|
4,915
|
3,910
|
3,550
|
3,550
|
3,550
|
Announcement Date
|
5/10/19
|
5/26/20
|
5/10/21
|
5/11/22
|
5/11/23
|
5/10/24
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
476,824
|
483,799
|
405,694
|
445,317
|
510,767
|
548,135
|
549,000
|
551,000
|
EBITDA
1 |
32,297
|
30,606
|
24,147
|
27,035
|
32,833
|
33,236
|
34,500
|
33,500
|
EBIT
1 |
17,989
|
13,977
|
8,263
|
11,566
|
16,078
|
15,854
|
18,750
|
21,750
|
Operating Margin
|
3.77%
|
2.89%
|
2.04%
|
2.6%
|
3.15%
|
2.89%
|
3.42%
|
3.95%
|
Earnings before Tax (EBT)
1 |
16,679
|
10,159
|
-176
|
9,124
|
4,710
|
9,857
|
29,750
|
19,050
|
Net income
1 |
11,211
|
3,730
|
7,126
|
5,381
|
-13,745
|
-6,707
|
20,750
|
12,750
|
Net margin
|
2.35%
|
0.77%
|
1.76%
|
1.21%
|
-2.69%
|
-1.22%
|
3.78%
|
2.31%
|
EPS
2 |
204.0
|
67.84
|
129.6
|
97.68
|
-248.4
|
-123.9
|
383.6
|
234.8
|
Free Cash Flow
1 |
4,263
|
6,907
|
-333
|
-4,147
|
2,989
|
3,276
|
4,819
|
16,800
|
FCF margin
|
0.89%
|
1.43%
|
-0.08%
|
-0.93%
|
0.59%
|
0.6%
|
0.88%
|
3.05%
|
FCF Conversion (EBITDA)
|
13.2%
|
22.57%
|
-
|
-
|
9.1%
|
9.86%
|
13.97%
|
50.15%
|
FCF Conversion (Net income)
|
38.03%
|
185.17%
|
-
|
-
|
-
|
-
|
23.22%
|
131.76%
|
Dividend per Share
2 |
34.00
|
30.00
|
20.00
|
40.00
|
40.00
|
45.00
|
50.00
|
60.00
|
Announcement Date
|
5/10/19
|
5/26/20
|
5/10/21
|
5/11/22
|
5/11/23
|
5/10/24
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2021 S1
|
2021 S2
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
249,907
|
191,735
|
213,959
|
109,880
|
216,977
|
111,548
|
116,792
|
228,340
|
109,299
|
134,570
|
243,869
|
130,600
|
136,298
|
266,898
|
122,400
|
141,272
|
263,646
|
133,073
|
151,416
|
284,489
|
132,750
|
138,000
|
142,000
|
143,000
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
10,174
|
-930
|
9,193
|
1,033
|
4,332
|
4,332
|
2,902
|
7,234
|
203
|
5,752
|
5,955
|
5,800
|
4,323
|
10,123
|
1,300
|
4,623
|
5,910
|
3,553
|
6,391
|
9,944
|
4,450
|
3,000
|
4,500
|
5,000
|
Operating Margin
|
4.07%
|
-0.49%
|
4.3%
|
0.94%
|
2%
|
3.88%
|
2.48%
|
3.17%
|
0.19%
|
4.27%
|
2.44%
|
4.44%
|
3.17%
|
3.79%
|
1.06%
|
3.27%
|
2.24%
|
2.67%
|
4.22%
|
3.5%
|
3.35%
|
2.17%
|
3.17%
|
3.5%
|
Earnings before Tax (EBT)
|
9,301
|
-7,735
|
-
|
-
|
2,216
|
5,214
|
-
|
-
|
-2,275
|
-
|
-4,264
|
6,116
|
-
|
-
|
254
|
-
|
3,304
|
2,658
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
7,889
|
-6,968
|
14,094
|
-227
|
2,464
|
3,729
|
-812
|
2,917
|
-2,161
|
-4,209
|
-6,370
|
4,400
|
-11,775
|
-7,375
|
-
|
2,125
|
2,163
|
-16,879
|
8,009
|
-8,870
|
1,300
|
-
|
-
|
-
|
Net margin
|
3.16%
|
-3.63%
|
6.59%
|
-0.21%
|
1.14%
|
3.34%
|
-0.7%
|
1.28%
|
-1.98%
|
-3.13%
|
-2.61%
|
3.37%
|
-8.64%
|
-2.76%
|
-
|
1.5%
|
0.82%
|
-12.68%
|
5.29%
|
-3.12%
|
0.98%
|
-
|
-
|
-
|
EPS
2 |
143.5
|
-126.7
|
256.3
|
-4.130
|
44.79
|
67.76
|
-14.87
|
52.89
|
-39.07
|
-76.05
|
-115.1
|
78.89
|
-212.1
|
-133.2
|
0.7000
|
38.41
|
39.11
|
-309.1
|
146.0
|
-163.0
|
23.50
|
-
|
-
|
-
|
Dividend per Share
|
20.00
|
-
|
-
|
-
|
20.00
|
-
|
-
|
-
|
-
|
-
|
20.00
|
-
|
-
|
-
|
-
|
-
|
20.00
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/6/19
|
11/9/20
|
5/10/21
|
11/8/21
|
11/8/21
|
2/7/22
|
5/11/22
|
5/11/22
|
8/10/22
|
11/10/22
|
11/10/22
|
2/6/23
|
5/11/23
|
5/11/23
|
8/7/23
|
11/13/23
|
11/13/23
|
2/7/24
|
5/10/24
|
5/10/24
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
36,317
|
26,361
|
25,020
|
21,231
|
15,871
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
4,263
|
6,907
|
-333
|
-4,147
|
2,989
|
3,276
|
4,819
|
16,800
|
ROE (net income / shareholders' equity)
|
12.9%
|
4.2%
|
7.5%
|
5%
|
-13.2%
|
-7.3%
|
21.6%
|
9.6%
|
ROA (Net income/ Total Assets)
|
5.91%
|
4.1%
|
2.49%
|
3.4%
|
4.24%
|
3.4%
|
-
|
-
|
Assets
1 |
189,794
|
90,923
|
286,202
|
158,198
|
-324,547
|
-197,541
|
-
|
-
|
Book Value Per Share
2 |
1,654
|
1,589
|
1,867
|
2,023
|
1,738
|
1,664
|
2,016
|
2,156
|
Cash Flow per Share
|
464.0
|
370.0
|
418.0
|
378.0
|
54.40
|
197.0
|
-
|
-
|
Capex
1 |
14,137
|
22,352
|
14,820
|
14,879
|
17,550
|
21,926
|
17,000
|
14,000
|
Capex / Sales
|
2.96%
|
4.62%
|
3.65%
|
3.34%
|
3.44%
|
4%
|
3.1%
|
2.54%
|
Announcement Date
|
5/10/19
|
5/26/20
|
5/10/21
|
5/11/22
|
5/11/23
|
5/10/24
|
-
|
-
|
Last Close Price
3,550
JPY Average target price
3,450
JPY Spread / Average Target -2.82% Consensus |
1st Jan change
|
Capi.
|
---|
| +21.53% | 1.12B | | +22.90% | 26.45B | | +34.86% | 5.18B | | +32.30% | 4.59B | | +12.14% | 1.38B | | +42.05% | 1.06B | | -27.01% | 972M | | -53.53% | 662M | | +2.46% | 409M | | -18.34% | 316M |
Other Office Equipment
|